THURSDAY, Aug. 25, 2022 (HealthDay News) -- Olokizumab is superior to placebo and noninferior to adalimumab in patients with rheumatoid arthritis receiving maintenance methotrexate, according to a study published in the Aug. 25 issue of the New England Journal of…
